Sionna Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SION and other ETFs, options, and stocks.

About SION

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. 

CEO
Michael Cloonan
CEOMichael Cloonan
Employees
59
Employees59
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2019
Founded2019
Employees
59
Employees59

SION Key Statistics

Market cap
230.27M
Market cap230.27M
Price-Earnings ratio
-2.35
Price-Earnings ratio-2.35
Dividend yield
Dividend yield
Average volume
5.84M
Average volume5.84M
High today
$5.49
High today$5.49
Low today
$4.47
Low today$4.47
Open price
$4.50
Open price$4.50
Volume
14.93M
Volume14.93M
52 Week high
$54.97
52 Week high$54.97
52 Week low
$4.01
52 Week low$4.01

Stock Snapshot

With a market cap of 230.27M, Sionna Therapeutics(SION) trades at $4.99. The stock has a price-to-earnings ratio of -2.35.

During the trading session on 2026-08-12, Sionna Therapeutics(SION) shares reached a daily high of $5.49 and a low of $4.47. At a current price of $4.99, the stock is +11.6% higher than the low and still -9.1% under the high.

Trading volume for Sionna Therapeutics(SION) stock has reached 14.93M, versus its average volume of 5.84M.

The stock's 52-week range extends from a low of $4.01 to a high of $54.97.

The stock's 52-week range extends from a low of $4.01 to a high of $54.97.

SION News

Simply Wall St 14h
Why Sionna Therapeutics Is Down 90.9% After Ending SION-719 Add-On To Trikafta Therapy

Sionna Therapeutics recently reported that its Phase 2a PreciSION CF trial of NBD1 stabilizer SION-719 added to Trikafta did not improve sweat chloride levels,...

Why Sionna Therapeutics Is Down 90.9% After Ending SION-719 Add-On To Trikafta Therapy
Quartz 21h
Sionna Therapeutics stock falls 92% after SION-719 trial failure - qz.com

...

Sionna Therapeutics stock falls 92% after SION-719 trial failure - qz.com
Nasdaq 5d
Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Key Points Vertex Pharmaceuticals could face competition in its most important market by far. The company is preparing for that by diversifying its lineup and...

Could 1 Tiny Biotech Topple Vertex Pharmaceuticals' Cystic Fibrosis Empire?

Analyst ratings

91%

of 11 ratings
Buy
9.1%
Hold
90.9%
Sell
0%

People also own

Based on the portfolios of people who own SION. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.